Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

How is New Innovation Giving a Much-Needed Boost to Women’s Health and Wellness? (Maddyness UK)

Related Content

Regeneron Sues Samsung Bioepis for Proposed Biosimilar of EYLEA in West Virginia District Court

A Practical Look at OIG’s New Compliance Guidance

Acuitas Files Suit Against CureVac Alleging Incorrect Inventorship on COVID MRNA-LNP Vaccine Patent Family

A Practical Look at OIG’s New Compliance Guidance

Genentech, Roche, and Biogen Sue Dr. Reddy’s and Fresenius for a Proposed Biosimilar of Rituxan in District of New Jersey

European Biologics Regulatory Updates

Significant 340B Drug Pricing Program Litigation May Impact 340B Scope

Significant 340B Drug Pricing Program Litigation May Impact 340B Scope

Contracting Away Your IP Rights: Pitfalls to Avoid With Third Party Partners During Drug Development

The British Legal Awards Name Goodwin Editor’s Choice Law Firm of the Year

Cell and Gene Therapies and Section 112: An Overview of the State of §112 Law and Considerations for Developers of Cell and Gene Therapies

Goodwin Welcomes SEC Alum Lynn to Lead Public Companies Team (Bloomberg Law)

Goodwin Strengthens Public Company Practice with New Hire (BNN)

Goodwin Hires Ex-SEC Lawyer (Law360)

Goodwin Hires Partner to Lead Public Company Practice (Reuters)

Q32 Bio and Homology Medicines To Merge

Life Sciences

Women's Health & Wellness

Healthcare